Buy & Sell AstraZeneca plc (AZN) – AstraZeneca plc Price Today
Aura AI Summary
Key Stats
- $280.85BMarket Cap
- HealthSector
- -13.48%3M Drawdown
- $307.09BEnterprise Value
- 1.73%Dividend Yield
- 98% Buy | 2% SellTrading Activity
- 124 daysTypical Hold Time
AstraZeneca plc (AZN) is currently valued at a market capitalization of $280.85B, with an enterprise value of $307.09B. Over the past 52 weeks, AstraZeneca plc has traded between a low of $132.46 and a high of $209.48, highlighting its annual price range. Over the past three months, AstraZeneca plc has recorded a drawdown of -13.48%, reflecting recent price volatility. AstraZeneca plc offers a dividend yield of 1.73%, with the most recent dividend of $1.60 paid on 20 Feb 26. On average, investors hold AstraZeneca plc for approximately 124 days, indicating typical investor behavior on the platform.
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Most Recent News
SanDisk's stock soars 4,050% post-spin-off, surpassing parent Western Digital's 1,077% gain.
SanDisk, spun off from Western Digital in early 2025, has seen its stock surge 4,050% in less than a year, outpacing Western Digital's 1,077% rally. This remarkable growth has made SanDisk's market value about $231 billion, exceeding Western Digital'...
Elon Musk joins Trump's China trip; Nvidia CEO Jensen Huang not invited amid US-China tech tensions.
Elon Musk will accompany former President Donald Trump on his upcoming trip to China, while Nvidia CEO Jensen Huang was notably excluded despite Nvidia's key role in US-China tech relations. The trip focuses on agriculture and aviation, with Boeing s...
AI boosts pharmaceutical packaging quality, cutting defects and costs with fast ROI and regulatory compliance.
AI technology is revolutionizing pharmaceutical packaging by enabling zero-defect production and meeting strict regulatory standards. Automated AI inspection systems deliver a 315% ROI with payback under four months, improve throughput by 32%, and re...